ERIS Stock Overview
Engages in the manufacture, marketing, and distribution of domestic branded formulations for chronic and sub-chronic therapies in India.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 2/6 |
Dividends | 2/6 |
Eris Lifesciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹1,274.60 |
52 Week High | ₹1,280.00 |
52 Week Low | ₹792.35 |
Beta | 0.36 |
11 Month Change | 18.73% |
3 Month Change | 41.47% |
1 Year Change | 59.20% |
33 Year Change | 75.07% |
5 Year Change | 235.60% |
Change since IPO | 111.90% |
Recent News & Updates
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Recent updates
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Shareholder Returns
ERIS | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 6.8% | 2.4% | 1.8% |
1Y | 59.2% | 57.0% | 45.5% |
Return vs Industry: ERIS exceeded the Indian Pharmaceuticals industry which returned 57% over the past year.
Return vs Market: ERIS exceeded the Indian Market which returned 45.5% over the past year.
Price Volatility
ERIS volatility | |
---|---|
ERIS Average Weekly Movement | 4.0% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 6.8% |
10% most volatile stocks in IN Market | 9.8% |
10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: ERIS's share price has been volatile over the past 3 months.
Volatility Over Time: ERIS's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 3,548 | Amit Bakshi | www.eris.co.in |
Eris Lifesciences Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, anti-infective, blood related, cardiovascular, dermatology, gastrointestinal, gastroenterology, haematinics, hormones, nero/ central nervous system, neuropsychiatry, otologicals, pain/analgesics, respiratory, stomatologicals, cosmetology, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions.
Eris Lifesciences Limited Fundamentals Summary
ERIS fundamental statistics | |
---|---|
Market cap | ₹173.45b |
Earnings (TTM) | ₹3.80b |
Revenue (TTM) | ₹22.47b |
45.6x
P/E Ratio7.7x
P/S RatioIs ERIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ERIS income statement (TTM) | |
---|---|
Revenue | ₹22.47b |
Cost of Revenue | ₹4.82b |
Gross Profit | ₹17.65b |
Other Expenses | ₹13.84b |
Earnings | ₹3.80b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 27.95 |
Gross Margin | 78.54% |
Net Profit Margin | 16.93% |
Debt/Equity Ratio | 86.3% |
How did ERIS perform over the long term?
See historical performance and comparison